Accessibility Menu
 
Fate Therapeutics logo

Fate Therapeutics

(NASDAQ) FATE

Current Price$1.29
Market Cap$149.98M
Since IPO (2013)-80%
5 Year-98%
1 Year+15%
1 Month+11%

Fate Therapeutics Financials at a Glance

Market Cap

$149.98M

Revenue (TTM)

$6.65M

Net Income (TTM)

$136.31M

EPS (TTM)

$-1.15

P/E Ratio

-1.12

Dividend

$0.00

Beta (Volatility)

1.61 (High)

Price

$1.29

Volume

28,863

Open

$1.36

Previous Close

$1.29

Daily Range

$1.27 - $1.36

52-Week Range

$0.91 - $1.94

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fate Therapeutics

Industry

Biotechnology

Employees

161

CEO

Bahram Valamehr, PhD, MBA

Headquarters

San Diego, CA 92131, US

FATE Financials

Key Financial Metrics (TTM)

Gross Margin

-94%

Operating Margin

-22%

Net Income Margin

-21%

Return on Equity

-52%

Return on Capital

-52%

Return on Assets

-43%

Earnings Yield

-89.29%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$149.98M

Shares Outstanding

116.26M

Volume

28.86K

Short Interest

0.00%

Avg. Volume

1.62M

Financials (TTM)

Gross Profit

$6.25M

Operating Income

$147.70M

EBITDA

$127.02M

Operating Cash Flow

$106.08M

Capital Expenditure

$5.95M

Free Cash Flow

$112.04M

Cash & ST Invst.

$203.66M

Total Debt

$77.85M

Fate Therapeutics Performance Analysis

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2025YOY CHG

Revenue

$1.37M

-26.4%

Gross Profit

$11.53M

-720.0%

Gross Margin

-8.42%

N/A

Market Cap

$149.98M

N/A

Market Cap/Employee

$828.61K

N/A

Employees

181

N/A

Net Income

$32.37M

+37.9%

EBITDA

$42.21M

-0.0%

Quarterly Fundamentals

Name
Q4 2025YOY CHG

Net Cash

$125.81M

-35.1%

Accounts Receivable

$916.00K

-74.1%

Inventory

$0.00

N/A

Long Term Debt

$73.29M

-5.9%

Short Term Debt

$4.56M

-38.5%

Return on Assets

-42.74%

N/A

Return on Invested Capital

-52.22%

N/A

Free Cash Flow

$24.51M

+12.2%

Operating Cash Flow

$23.31M

+16.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
MOLNMolecular Partners AG
$4.20+1.45%
ABOSAcumen Pharmaceuticals, Inc.
$2.72+1.49%
NKTXNkarta, Inc.
$2.42+5.68%
CRBPCorbus Pharmaceuticals Holdings, Inc.
$10.00-0.20%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$13.30+0.15%
SMRNuScale Power
$11.71+0.14%
TQQQProShares Trust - ProShares UltraPro Qqq
$55.65+0.04%
SQQQProShares Trust - ProShares UltraPro Short Qqq
$59.44-0.04%

Questions About FATE

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.